Hologic stock (US4364401012): Blackstone and TPG acquisition nears completion

Blackstone and TPG Global are acquiring Hologic in an all-cash deal expected to close on or about April 7, 2026, marking a significant transition for the women's health diagnostics leader.

Hologic, a leading global medical technology company specializing in women's health diagnostics and surgical solutions, is undergoing a transformative acquisition by affiliates of Blackstone Inc. and TPG Global. The all-cash transaction is expected to be completed on or about April 7, 2026, according to OTC Markets as of May 14, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hologic, Inc.
• Sector/industry: Medical devices, women's health diagnostics, surgical solutions
• Headquarters/country: United States
• Core markets: Diagnostic imaging, surgical products, women's health
• Key revenue drivers: Breast imaging, gynecological surgical devices, molecular diagnostics
• Home exchange/listing venue: NASDAQ (HOLX)
• Trading currency: USD

Hologic: core business model

Hologic operates as a comprehensive medical technology platform focused on women's health and diagnostic solutions. The company's portfolio spans breast imaging systems, including the widely adopted 3Dimensions mammography platform, gynecological surgical devices, and molecular diagnostic testing capabilities. The company serves healthcare providers, hospitals, and diagnostic laboratories across North America and international markets, positioning itself as a critical player in preventive and diagnostic care for women's health conditions.

Main revenue and product drivers for Hologic

Hologic's revenue streams are anchored in three primary segments: diagnostic imaging, surgical products, and molecular diagnostics. The breast imaging division, featuring advanced digital mammography and 3D tomosynthesis systems, represents a substantial portion of revenue. The surgical segment includes endometrial ablation and other gynecological interventions. Molecular diagnostics, particularly infectious disease testing, contributes to growth as the molecular infectious disease testing market is projected to expand from approximately USD 11.30 billion in 2026 to USD 19.09 billion by 2031, at a compound annual growth rate of 11.1%, according to MarketsandMarkets as of May 13, 2026.

Strategic acquisition and market implications

The Blackstone and TPG acquisition represents a significant capital event for Hologic shareholders and signals confidence in the company's market position and growth trajectory. Private equity ownership may enable accelerated investment in research and development, geographic expansion, and potential bolt-on acquisitions within the women's health and diagnostics sectors. For US investors, the transaction underscores the strategic value of diagnostic imaging and women's health solutions in the broader healthcare market, where demographic trends and aging populations drive sustained demand for preventive screening and diagnostic tools.

Conclusion

Hologic's acquisition by Blackstone and TPG Global marks a pivotal transition for the medical technology company, moving from public market listing to private ownership. The transaction reflects the strategic importance of women's health diagnostics and surgical solutions in the healthcare landscape. US investors previously holding Hologic shares should monitor the deal closure timeline and any regulatory approvals required for completion. The acquisition underscores sustained investor confidence in diagnostic imaging and women's health markets despite broader healthcare sector volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.